Boiron SA (BOI)
Euronext Paris · France · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 18.15 |
|---|---|
| 52-week range | 16.90 – 30.73 |
| Return, 1 month / 3 months | −14.0% / −32.3% |
| Return, 1 year / 3 years | −31.5% / −47.1% |
| Trend | Below its 200-day average |
| RSI (14) | 33 |
| Volatility (1 year) | 32.3% |
| Worst drawdown (1 year) | -44.1% |
| Average daily value traded | 0.08M EUR |
| Dividend yield | 7.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Boiron is a French company that makes homeopathic medicines. Its products include single-ingredient and multi-ingredient homeopathic remedies, specialty preparations and care products, which are supplied mainly to pharmacies and health stores. The company also provides homeopathic preparations for use by healthcare professionals. Boiron is based in France, near Lyon, and its remedies are distributed in many countries through pharmacy channels.
Boiron SA trades under the code BOI on the Euronext Paris in France, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Boiron SA (BOI) trades on the Euronext Paris in France. It last closed at EUR 18.15 on 19 October 2026.
Its price-based Market X-Ray is 40 out of 100 (a weak price profile), ranking 428 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 31.5% and over the last three months it fell 32.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 24 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -29.8% | ||
| From 52-week high | -39.9% | ||
| Momentum | 22 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -32.3% | ||
| 6-month return | -25.9% | ||
| 12-month return, skipping the last month | -20.4% | ||
| Risk (lower is better) | 50 · Weak | Volatile, with deep drawdowns. | |
| Volatility (1 year) | 32.3% | ||
| Worst drawdown (1 year) | -44.1% | ||
| Liquidity | 62 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.08M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 72 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 7.4% | ||
| Years with dividends | 5 |
Strengths
- Income: Dividend is high and has been paid regularly.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Risk (lower is better): Volatile, with deep drawdowns.
Returns
| 1 week | +5.2% |
|---|---|
| 1 month | −14.0% |
| 3 months | −32.3% |
| 6 months | −25.9% |
| 1 year | −31.5% |
| 3 years | −47.1% |
| 5 years | −35.1% |
Signals
| 50-day / 200-day average | 22.92 / 25.84 |
|---|---|
| Golden / death cross (60 days) | Death, 34 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.83 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 3 Jun 2026 | EUR 1.3500 |
| 3 Jun 2025 | EUR 1.2000 |
| 3 Jun 2024 | EUR 1.3500 |
| 18 Oct 2023 | EUR 10.3600 |
| 1 Jun 2023 | EUR 1.1000 |
| 1 Jun 2022 | EUR 0.9500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.